Cytokinetics, Incorporated
CYTK
Jodie situation report
Cytokinetics, Incorporated's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 18 directly disclosed connections are confirming.
- FDA placed a partial clinical hold on CK-089 that limited dosing at plasma exposures above certain levels.
Invalidation: The isolated read changes if CYTK's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind CYTK
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
SNYSanofipartnerFeb 26, 2026 ▾
“In December 2024, Corxel assigned its rights and obligations under our license and collaboration agreement to Genzyme Corporation, an affiliate of Sanofi.”
AMGNAmgen Inc.investeeFeb 26, 2026 ▾
“2017 RP Omecamtiv Mecarbil Royalty Purchase Agreement In February 2017, we entered into the RP OM RPA pursuant to which we sold a portion of our right to receive royalties from Amgen on future net sales of omecamtiv mecarbil to RPFT for a one-time payment of…”
Depended on by
EWTXEdgewise Therapeutics, Inc.competitorMay 7, 2026 ▾
“In the field of emerging treatments for HCM, competitors include Bristol-Myers Squibb (BMS), Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, and Celltrion, and Braveheart Bio.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 15 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CYTK is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.